These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24006142)

  • 61. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.
    Brauner S; Eriksson-Dufva A; Hietala MA; Frisell T; Press R; Piehl F
    JAMA Neurol; 2020 Aug; 77(8):974-981. PubMed ID: 32364568
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An antibody treats almost all refractory autoimmune diseases: fact and beyond.
    Lin LY; Hsu MH; Yang KD
    J Formos Med Assoc; 2012 Apr; 111(4):181-2. PubMed ID: 22655322
    [No Abstract]   [Full Text] [Related]  

  • 63. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
    Reddy V; Jayne D; Close D; Isenberg D
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rituximab for myasthenia gravis developing after bone marrow transplant.
    Zaja F; Russo D; Fuga G; Perella G; Baccarani M
    Neurology; 2000 Oct; 55(7):1062-3. PubMed ID: 11061276
    [No Abstract]   [Full Text] [Related]  

  • 65. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
    Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
    Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rituximab-treated patients have a poor response to influenza vaccination.
    Eisenberg RA; Jawad AF; Boyer J; Maurer K; McDonald K; Prak ET; Sullivan KE
    J Clin Immunol; 2013 Feb; 33(2):388-96. PubMed ID: 23064976
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.
    Nakou M; Katsikas G; Sidiropoulos P; Bertsias G; Papadimitraki E; Raptopoulou A; Koutala H; Papadaki HA; Kritikos H; Boumpas DT
    Arthritis Res Ther; 2009; 11(4):R131. PubMed ID: 19715572
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old.
    Doughty CT; Suh J; David WS; Amato AA; Guidon AC
    Muscle Nerve; 2021 Dec; 64(6):651-656. PubMed ID: 34378210
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
    Toubi E
    Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia.
    Fujimaki K; Takasaki H; Koharazawa H; Takabayashi M; Yamaji S; Baba Y; Kanamori H; Ishigatsubo Y
    Leuk Lymphoma; 2005 Jul; 46(7):1101-2. PubMed ID: 16019566
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse?
    Triplett JD; Hardy TA; Riminton DS; Chu SYK; Reddel SW
    Muscle Nerve; 2019 Sep; 60(3):307-311. PubMed ID: 31177576
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Acute painful lumbosacral paresthesia after intrathecal rituximab.
    Bromberg JE; Doorduijn JK; Baars JW; van Imhoff GW; Enting R; van den Bent MJ
    J Neurol; 2012 Mar; 259(3):559-61. PubMed ID: 21830092
    [No Abstract]   [Full Text] [Related]  

  • 73. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
    Jonsson DI; Pirskanen R; Piehl F
    Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Letter: Decreased serum-IgA in myasthenia gravis.
    Behan PO; Simpson JA; Behan WM
    Lancet; 1976 Mar; 1(7959):593-4. PubMed ID: 55875
    [No Abstract]   [Full Text] [Related]  

  • 75. CD19+ Tim-1+ B cells are decreased and negatively correlated with disease severity in Myasthenia Gravis patients.
    Zhang Y; Zhang X; Xia Y; Jia X; Li H; Zhang Y; Shao Z; Xin N; Guo M; Chen J; Zheng S; Wang Y; Fu L; Xiao C; Geng D; Liu Y; Cui G; Dong R; Huang X; Yu T
    Immunol Res; 2016 Dec; 64(5-6):1216-1224. PubMed ID: 27677768
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Myocardial infarction after rituximab infusion.
    Renard D; Cornillet L; Castelnovo G
    Neuromuscul Disord; 2013 Jul; 23(7):599-601. PubMed ID: 23768984
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab.
    Chan F; Swayne A; Gillis D; Walsh M; Henderson RD; McCombe PA; Wong RC; Blum S
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):955-956. PubMed ID: 30455407
    [No Abstract]   [Full Text] [Related]  

  • 78. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.
    Stathopoulos P; Kumar A; Heiden JAV; Pascual-Goñi E; Nowak RJ; O'Connor KC
    Ann N Y Acad Sci; 2018 Jan; 1412(1):154-165. PubMed ID: 29381221
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bilateral simultaneous acute anterior interosseous neuropathy after treatment with rituximab.
    Green SL; Hegde V
    Muscle Nerve; 2019 Nov; 60(5):E26-E27. PubMed ID: 31415095
    [No Abstract]   [Full Text] [Related]  

  • 80. Rituximab in Myasthenia Gravis - Where do we stand?
    Siddiqi ZA; Khan W; Hussain FS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1013-1023. PubMed ID: 33566716
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.